Skip to content
Bioventus logo

Bioventus

BVS

Bioventus is a global medical device company dedicated to musculoskeletal health and pain management.

Market cap
$843.46M+94.4%
Revenue$576.3M+1.5%
Net income$28.5M+184%
Free cash flow$100.6M+321%
EPS (diluted)$0.41+179%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$155.6M
EPS estimate$0.22

Financials

Q1 2026

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation & ratios

Valuation

See full
Market cap$843.46M+94.4%
Enterprise value$1.1B+44.0%
P/E29.6×
P/S1.5×+0.7×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Segments

By product

See full
Pain Treatments$63.4M+7.7%
Surgical Solutions$48.0M+6.2%
Restorative Therapies$20.6M+4.6%

By segment

See full
U.S. Segment$116.4M+5.4%
International Segment$15.6M+17.1%

Competitors

Profile

Bioventus is a global medical device company dedicated to musculoskeletal health and pain management. The company develops and commercializes clinically proven solutions designed to relieve pain, facilitate bone fusion, and accelerate fracture healing through a diverse portfolio of minimally invasive and surgical technologies.

Competitive position

A leading provider of orthobiologic and ultrasonic surgical solutions with a dominant position in the non-invasive fracture healing market.

GeographiesUnited States, Europe, Asia-Pacific, Canada
Customer segmentsHospitals, Ambulatory Surgery Centers, Specialist Physician Clinics
Business modelDirect-to-hospital sales, Specialized distribution, Medical device manufacturing
SuppliersRaw material suppliers for hyaluronic acid, Specialized electronics manufacturers, Biologic tissue processors
CustomersHospitals, Surgical centers, Orthopedic clinics, Group Purchasing Organizations (GPOs)
Listed2021
Employees995.0
CEORobert Claypoole
FilingsSEC EDGAR

Questions, answered.

What is Bioventus's market cap?
Bioventus (BVS) has a market capitalization of $843.5M and trades on NASDAQ.
What is Bioventus's revenue and profitability?
Bioventus generated $576.3M in trailing twelve-month revenue with net income of $28.5M, representing a net margin of 4.9%. Gross margin stands at 68.7%, with free cash flow of $100.6M. These figures are based on the Q1 2026 filing.
Who are Bioventus's competitors?
Bioventus's key competitors include Anika Therapeutics, Zimmer Biomet, Medtronic, and others. These companies compete in similar markets and product categories.
Who does Bioventus partner with?
Bioventus's notable partners include Seikagaku Corporation.
What subsidiaries does Bioventus have?
Bioventus's subsidiaries include Bioventus LLC, Misonix, Inc., Bioness Inc..
Where is Bioventus headquartered?
Bioventus is headquartered in United States of America and employs approximately 995 people. It has been publicly traded since 2021.